KBY Biotech Indexv0.0.34
Search
← Pipeline|SOB-2861

SOB-2861

Phase 2
By Sobi
Source: Trial-derived·Trials: 2
Modality
Degrader
MOA
DLL3 ADC
Target
RET
Pathway
STING
CKD
Development Pipeline
Preclinical
~May 2019
→ ~Aug 2020
Phase 1
~Nov 2020
→ ~Feb 2022
Phase 2
May 2022
→ May 2026
Phase 2Current
NCT03088559
1,729 pts·CKD
2022-05→2025-10·Completed
NCT05802755
2,310 pts·CKD
2023-10→2026-05·Completed
4,039 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-10-146mo agoPh2 Data· CKD
2026-05-262mo awayPh2 Data· CKD
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P2
Complet…
P2
Complet…
Catalysts
Ph2 Data
2025-10-14 · 6mo ago
CKD
Ph2 Data
2026-05-26 · 2mo away
CKD
Completed|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT03088559Phase 2CKDCompleted1729NT-proBNP
NCT05802755Phase 2CKDCompleted2310VA
Competitors (10)
DrugCompanyPhaseTargetMOA
RHH-5389RochePreclinicalRETSTINGag
NVS-4076NovartisPreclinicalTROP-2DLL3 ADC
RimamavacamtenMerck & CoPhase 1PI3KαDLL3 ADC
FixanesiranAbbViePreclinicalRETJAK1/2i
BMY-8678Bristol-Myers SquibbApprovedRETMDM2i
AMG-9654AmgenPhase 2GPRC5DDLL3 ADC
VRT-1576Vertex PharmaPhase 2/3RETSHP2i
ARG-3458ArgenxPreclinicalRETIL-17i
NidaratamabKrystal BiotechPreclinicalRETIL-17i
TixatapinarofArvinasPhase 1/2CDK2DLL3 ADC